Lovett, Jacqueline

Antidepressant-relevant concentrations of the ketamine metabolite (2 R ,6 R )-hydroxynorketamine do not block NMDA receptor function

Lumsden, E. W., Troppoli, T. A., Myers, S. J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.-H., Schmidt, S., et al. (2019) · Proceedings of the National Academy of Sciences

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 158

( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions

Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., Thomas, C. J., Moaddel, R., Zarate, C. A., et al. (2019) · Proceedings of the National Academy of Sciences

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 152

Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression

Farmer, C. A., Gilbert, J. R., Moaddel, R., George, J., Adeojo, L., Lovett, J., Nugent, A. C., Kadriu, B., Yuan, P., Gould, T. D., et al. (2020) · Neuropsychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 85

(R)‐Ketamine exerts antidepressant actions partly via conversion to (2R,6R)‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses

Zanos, P., Highland, J. N., Liu, X., Troppoli, T. A., Georgiou, P., Lovett, J., Morris, P. J., Stewart, B. W., Thomas, C. J., Thompson, S. M., et al. (2019) · British Journal of Pharmacology

Treatment of Major DepressionTryptophan and brain disorders

Cited by 82

Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ( 2R,6R )-hydroxynorketamine

Highland, J. N., Morris, P. J., Zanos, P., Lovett, J., Ghosh, S., Wang, A. Q., Zarate, C. A., Thomas, C. J., Moaddel, R., & Gould, T. D. (2019) · Journal of Psychopharmacology

Treatment of Major DepressionPharmacogenetics and Drug Metabolism

Cited by 62

A brain proteomic signature of incipient Alzheimer’s disease in young APOE ε4 carriers identifies novel drug targets

Roberts, J. A., Varma, V. R., An, Y., Varma, S., Candia, J., Fantoni, G., Tiwari, V., Anerillas, C., Williamson, A., Saito, A., et al. (2021) · Science Advances

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 49

Assessment of NAD(+)metabolism in human cell cultures, erythrocytes, cerebrospinal fluid and primate skeletal muscle

Demarest, T. G., Truong, G. T. D., Lovett, J., Mohanty, J. G., Mattison, J. A., Mattson, M. P., Ferrucci, L., Bohr, V. A., & Moaddel, R. (2019) · Analytical Biochemistry

Sirtuins and Resveratrol in MedicineMetabolomics and Mass Spectrometry Studies

Cited by 48

Ketamine for Refractory Chronic Migraine: An Observational Pilot Study and Metabolite Analysis

Schwenk, E. S., Torjman, M. C., Moaddel, R., Lovett, J., Katz, D., Denk, W., Lauritsen, C., Silberstein, S. D., & Wainer, I. W. (2021) · The Journal of Clinical Pharmacology

Migraine and Headache StudiesPain Mechanisms and Treatments

Cited by 20